Celgene (CELG) is expected to report Q1 earnings before the market open on Thursday, April 26 with a conference call scheduled for 9:00 am ET.
Analysts are looking for EPS of $1.13 on revenue of $1.32B. The consensus range is $1.06-$1.21 for EPS, and $1.27B-$1.34B for revenue, according to First Call. After narrowly missing EPS and revenue guidance in Q4, it gave a FY12 EPS forecast of $4.70-$4.80 and FY12 revenue forecast of $5.4B-$5.6B. It also expects FY12 Revlimid sales $3.75B-$3.85B and Abraxane sales to grow to $1B-$1.25B by 2015. The company also said it expects 2013 as the target year for an initial regulatory submission for Apremilast. Investors will be looking to hear more details on the growth of these and other drugs, with Revlimid as its largest moneymaker.
In the past quarter, Celgene acquired Aceytylon and Avila, though the latter is expected to be neutral to the FY12 guidance. Celgene was initiated with an Overweight at Morgan Stanley and a Buy at Cantor. Celgene's target price was also raised at Citigroup, Summer Street, and RW Baird, citing an expectation that shares will continue to outperform. It was, however, downgraded to Hold at Auriga and Argus, citing valuation.